Reata Pharmaceuticals has been acquired by Biogen. Please visit www.biogen.com for more information.

Get to Know This Progressively Degenerative Disease

genetic-testing

The sooner Friedreich’s ataxia (FA) is confirmed with the right genetic test, the sooner you can guide your patients to optimal supportive care.3

multidisciplinary-care-team

FA is a multisystem disease, so it is critical to connect patients and their families to the multidisciplinary support they need.4

mFARS-exam.png

The modified Friedreich’s Ataxia Rating Scale (mFARS) is a clinically validated neurological assessment and provides a detailed evaluation of a patient’s status. The mFARS can provide a clear picture of the relentless progression of FA and its severe impact on patient function.5

Stay Connected

Sign up to receive the latest news and resources for FA.

I authorize Reata Pharmaceuticals, Inc. (Reata), to send me emails regarding Friedreich's ataxia, genetic testing, and other informational materials. I understand that I may revoke this authorization and choose not to receive information from Reata by clicking the “unsubscribe” link provided in emails I receive from Reata. I have read and understand Reata’s Privacy Notice.

References: 1. National Institute of Neurological Disorders and Stroke. Friedreich Ataxia Fact Sheet. November 15, 2021. Accessed March 16, 2022. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Friedreichs-Ataxia-Fact-Sheet. 2. Schulz JB, Boesch S, Bürk K, et al. Diagnosis and treatment of Friedreich ataxia: a European perspective. Nat Rev Neurol. 2009;5(4):222-234. 3. Fogel BL, Perlman S. Clinical features and molecular genetics of autosomal recessive cerebellar ataxias. Lancet Neurol. 2007;6(3):245-257. 4. de Silva RN, Vallortigara J, Greenfield J, Hunt B, Giunti P, Hadjivassiliou M. Diagnosis and management of progressive ataxia in adults. Pract Neurol. 2019;19(3):196-207. 5. Rummey C, Corben LA, Delatycki MB, et al. Psychometric properties of the Friedreich Ataxia Rating Scale. Neurol Genet. 2019;5(6):371.

You are now leaving ThinkFA.com

You are now leaving ThinkFA.com. Links are provided as a convenience and for general informational purposes only. Reata does not control the site you are going to. It is recommended you carefully review the terms of use and privacy statement of any other sites. You are solely responsible for your interactions.

Go Back Leave

You are now leaving ThinkFA.com

You will be going to ConnectFA.com, a Reata website for patients and caregivers. ConnectFA.com contains links that are provided as a convenience and for general informational purposes. These links are not controlled by Reata. It is recommended you carefully review the terms of use and privacy statements of any other sites. You are solely responsible for your interactions.

Go Back Leave